Quality assurance guidelines for testing using the OraQuick rapid HIV-1 antibody test by Centers for Disease Control and Prevention (U.S.)
 Appendix: Quality Assurance Guidelines for Testing Using the OraQuick 
Rapid HIV-1 Antibody Test 
 
 
Overview This appendix includes several items to facilitate conducting testing and 
performing quality assurance using the OraQuick Rapid HIV-1 Antibody test.  
The forms provided are examples and templates that can be adapted for local use, 
adding or deleting fields, as needed.  The appendix includes the following: 
A.  Government regulations 
B. Example training checklist for the OraQuick Rapid HIV-1 Antibody Test 
C. Example of a temperature log 
D. Example log of quality control results 
E. Example log of test results  
F. Example specimen transfer log 
G. External assessment: proficiency testing and other mailed evaluation 
programs  
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Appendix A 
Government Regulations  
 
Food and Drug 
Administration 
(FDA) sales 
restrictions 
To help ensure the quality of testing with the OraQuick test, the FDA approved 
the test kit it with specific restrictions for its sale.  These restrictions apply to the 
waived test kit.  By purchasing the test, the customer agrees to follow these 
restrictions.  The restrictions are outlined below (for the specific FDA language, 
refer to the OraQuick package insert).  The kit purchaser must:   
Be a clinical laboratory, i.e., holds a certificate from the Federal government 
(Clinical Laboratory Improvement Act of 1988 (CLIA) certificate – see below 
for details) and any state or other certification that is required.    
Have an established quality assurance program. 
Provide training for testing personnel (operators) using the instructional 
materials provided by the manufacturer. 
Provide information to persons being tested by giving each a copy of the 
manufacturer’s “Subject Information” pamphlet prior to specimen collection 
and appropriate information when providing the test results.   
Not use the kit to screen blood or tissue donors. 
 
Clinical 
Laboratory 
Improvement 
Amendment 
(CLIA) regulations 
The OraQuick test is a waived test under Federal regulations—the regulations for 
the Clinical Laboratory Improvement Amendments of 1988 (CLIA regulations).  
As a waived test, Federal requirements for the OraQuick test are minimal.  The 
CLIA requirements for sites wishing to offer testing using the OraQuick test are 
listed below and can be found at http://www.phppo.cdc.gov/clia/regs/toc.asp.  
Each site must: 
 
 
 
 
Have a valid CLIA certificate of waiver, certificate of compliance or 
certificate of accreditation.  
Follow the manufacturer’s instructions for performing the test, and 
Permit announced or unannounced inspections by representatives of the 
Centers for Medicare & Medicaid Services (CMS) under certain 
circumstances (see §493.35(d) in the regulations at the Web site listed above). 
Perform only waived tests if holding a certificate of waiver. 
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Government Regulations (continued) 
 
How to obtain a 
CLIA certificate 
All sites planning to offer only the OraQuick test that are not already CLIA 
certified, must obtain a Certificate of Waiver or be included under a multiple site 
exception, such as limited public health testing or mobile testing.  To obtain a 
Certificate of Waiver, complete Form CMS-116, found at the following CMS 
Internet address: http://www.cms.gov/clia/cliaapp.asp.  This form asks for 
information on the facility type (select from a list), hours of operation, estimated 
annual number of waived tests to be performed, the type of control (nonprofit, for 
profit or government control) and the total number of individuals involved in 
performing testing.  The facility owner or laboratory director must sign the form. 
Mail the completed form to the State agency in which your site is located.  To find 
your State agency contact, refer to the information provided at the following 
Internet address http://www.cms.gov/clia/ssa-map.asp.  After the completed form 
is processed by the State agency, a fee of $150 will be assessed for a Certificate of 
Waiver.  The certificate is valid for two years.   
 
State regulations 
 
In addition to CLIA, some States have specific regulatory requirements for HIV 
testing.  Contact your State agency for information on State requirements.  State 
agency contacts are listed at http://www.cms.gov/clia/ssa-map.asp. 
 
Occupational safety 
and health 
regulations   
Employers with employees who have an occupational exposure to blood or other 
potentially infectious materials must meet the U.S. Department of Labor 
Occupational Health and Safety Administration (OSHA) standards for bloodborne 
pathogens.  Individuals collecting blood specimens or performing the OraQuick 
test have exposure to blood or other potentially infectious materials resulting from 
the performance of their duties.  Therefore, sites offering the OraQuick test must 
meet OSHA standards that include, but are not limited to, the following 
requirements: 
 

Have a written Exposure Control Plan. 
Provide personal protective equipment, such as gloves.  
Make available the hepatitis B vaccine and vaccination series to all employees 
who have occupational exposure.  
Provide post-exposure evaluation and follow-up to all employees who have 
had an exposure incident.  
 Provide training for all employees with occupational exposure. 
 Contain and dispose of biohazard waste following applicable regulations 
(includes blood and items contaminated with blood or other potentially 
infectious materials).  Refer to state and local regulations regarding disposal 
of biohazardous materials.  
NOTE:  This is an overview of OSHA requirements and is not a complete list.  
For specific information, visit the OSHA Web site at 
http://www.osha.gov/SLTC/bloodbornepathogens/index.html.   
 
 
 
 
 
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Appendix B 
Example Training Checklist for the OraQuick Rapid HIV-1 Antibody Test 
 
Employee:  Name_________________________ 
 
Instructions:  Fill in dates when the trainee observes and performs each objective or procedural step, as 
applicable. (If a trainee will not perform a specific task, enter N/A for not applicable.)  The trainee should 
initial when he/she feels the objective/procedure has been mastered and the trainer when he/she thinks the 
trainee has met the objective or performs the specific procedure competently. 
 
Objective/Procedural Step Date 
Observed 
Date 
Performed 
Trainee’s 
initial and 
date 
Trainer’s 
initial and 
date  
Read OraQuick procedure N/A  
 
  
Read Biohazard Exposure Control Plan 
 
N/A    
Determine if requirements for acceptable 
testing environment are met (e.g.,  
temperature, lighting, level work space)  
    
Practice test with negative and positive 
external controls 
    
Give person getting tested the “Subject 
Information” brochure 
    
Label test device components and 
appropriate paperwork 
 
 
   
Collect finger-stick specimen, put loop 
into vial and mix correctly 
 
 
   
Insert test device, time test, read result     
Dispose of lancet and other biohazardous 
waste appropriately 
 
 
   
Record results on report form and log 
sheet 
    
Record internal and external quality 
control (QC) results in QC log 
    
Evaluate a new OraQuick test kit lot 
number and record results in QC log 
    
Report test result to the person being 
tested (one negative and one preliminary 
positive) 
    
Refer person or collect specimen for 
confirmatory testing 
    
Send confirmatory test specimen to 
referral laboratory and document 
submission 
    
Receive referral laboratory results and 
record results 
    
Explain what to do if QC results show a 
problem 
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Appendix C 
Example Temperature Log 
 
Thermometer location ________________________________ 
 
Acceptable temperature range* _________________________    
 
Month/Year ___________________ 
 
 
Day Temperature  Initials  Day Temperature Initials  
1   17   
2   18   
3   19   
4   20   
5   21   
6   22   
7   23   
8   24   
9   25   
10   26   
11   27   
12   28   
13   29   
14   30   
15   31   
16      
 
*The acceptable range for test kit storage is 2o to 27o C or 35o to 80o F; the acceptable range for control kit 
storage is 2o to 8oC or 35o to 46o F; the acceptable range for the testing area is 15o to 27o C or 59o to 80o F.  
NOTE:  Periodically (e.g., every six months) check thermometer performance and document.  
 
Corrective Action 
Date Action Taken Initials 
   
   
   
   
   
   
   
 
 
Reviewed by and date ________________________________________________________________
 
 Appendix D 
Example Log of Control Results 
 
Date 
 
Time Test Kit Lot 
# 
Test 
Kit 
Exp. 
Date* 
New 
Lot #, 
ship- 
ment ? 
Control Kit 
Lot # 
Control 
Kit Exp. 
Date 
Date 
controls 
opened 
Negative 
Control 
Result 
Positive 
Control 
Result 
Results 
Accept-
able? 
Performed 
by 
Reviewed 
by and Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
            
            
            
            
            
            
            
            
            
            
*Exp. = Expiration 
 
Corrective Action (use reverse side, if needed) 
  Date Action Taken Initials Reviewed by and date 
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 Appendix E 
Example Log of Test Results  
 
Confirmatory Testing Reviewed 
by and 
Date 
Test 
Subject 
ID* 
Date  and 
Time 
Specimen 
Collected 
Kit Lot 
Number 
Kit 
Expiration 
Date 
Actual 
Test 
Incubation 
Time  
Test result 
N=non-
reactive 
R=reactive
I=invalid  
 
Tester Result 
and 
Time 
Reported 
to 
Subject  
 
Track-
ing # 
Specimen 
type 
(blood or 
oral 
fluid) 
Result Date 
result 
received 
Date 
result 
given 
to test 
subject 
 
 
 
 
 
 
 
 
 
             
 
 
             
 
 
             
 
 
             
 
 
             
 
 
              
              
              
              
              
              
             
*ID = Identification 
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 Appendix F 
Example Specimen Transfer Log 
 
[Put Referring Facility Name,  
Address and Phone Number here] 
 
Date:_______________________ 
 
Referral Laboratory _________________________________ 
 
Specimen 
Tracking 
Number 
Test 
Subject 
ID* 
OraQuick 
Test Result 
Date 
Specimen 
Collected 
Time 
Specimen 
Collected 
Collected 
by 
Referral 
Lab Req† 
Completed 
(9) 
Date Conf 
Result 
Received 
Confirm 
Test 
Result 
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
       
 
  
*ID = Identification 
†Lab Req = Laboratory Requisition 
(NOTE:  If you use more than one referral laboratory, add a column to record each one.) 
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 Appendix G 
External Assessment: Proficiency Testing and Other Mailed Evaluation 
Programs 
 
Background and 
overview 
Some States may require participation in a State or Centers for Medicare & 
Medicaid Services (CMS)-approved proficiency testing program, even though this 
program is not required by CLIA for waived tests.  Participating in proficiency 
testing or an external evaluation program is a relatively easy way to obtain an 
external assessment of the quality of waived testing.  There are several programs 
in which a site may choose to enroll. Test samples will be received by mail on a 
periodic basis, usually two to three times per year.  These samples include a 
combination of several (typically five) HIV antibody positive and negative 
specimens with results known to the program provider, but not to the participants.  
The participants test the samples as if they were client/patient specimens and send 
results back to the program provider.   
 
Evaluation reports In proficiency testing programs, the results from the individual participant sites 
are compared to the expected values.  Each site receives a graded individualized 
report and summary report showing their performance and the performance of all 
the participants.  In some evaluation programs, such as the Model Performance 
Evaluation Program (MPEP) offered by the Centers for Disease Control and 
Prevention (CDC), individual participant results are not graded; instead a 
summary report is provided with a compilation of results from all participants and 
a commentary on overall performance. 
 
For more 
information 
For more information, refer to the following Internet sites: 
 The CDC MPEP for rapid HIV testing can accommodate a limited number of 
additional sites.  For more information and to enroll on-line go to the 
following Web sites: http://www.phppo.cdc.gov/mpep/default.asp, 
http://www.phppo.cdc.gov/mpep/enrollment.asp.  There is currently no fee to 
enroll in the MPEP program.  
 For a list of CLIA approved proficiency testing programs (several of which 
include HIV testing) go to http://www.cms.gov/clia/ptlist.pdf.  This list 
includes contact information for each program and the tests offered.  These 
programs charge an enrollment fee. 
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